Last reviewed · How we verify
scopolamine patch
Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting.
Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting. Used for Prevention of nausea and vomiting associated with motion sickness, Prevention of postoperative nausea and vomiting.
At a glance
| Generic name | scopolamine patch |
|---|---|
| Also known as | Transderm-Scop, Scopace, Maldemar, Scopolamine, Scopolamine Challenge |
| Sponsor | Rutgers, The State University of New Jersey |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptors (M1, M3, M5) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Neurology |
| Phase | FDA-approved |
Mechanism of action
Scopolamine is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors, particularly in the chemoreceptor trigger zone and vestibular nuclei of the brain. By inhibiting these receptors, it suppresses signals that trigger the vomiting reflex and reduces motion-induced nausea. The transdermal patch formulation provides sustained drug delivery over several days.
Approved indications
- Prevention of nausea and vomiting associated with motion sickness
- Prevention of postoperative nausea and vomiting
Common side effects
- Dry mouth
- Drowsiness
- Blurred vision
- Dizziness
- Mydriasis (dilated pupils)
Key clinical trials
- Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy (PHASE3)
- Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging (NA)
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
- Toward a Computationally-Informed, Personalized Treatment for Hallucinations (EARLY_PHASE1)
- Anesthetic Optimization in Pediatric LeFort Surgeries (NA)
- Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery (PHASE3)
- Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? (PHASE3)
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- scopolamine patch CI brief — competitive landscape report
- scopolamine patch updates RSS · CI watch RSS
- Rutgers, The State University of New Jersey portfolio CI